Apr 29, 2020   SOURCE: PR NewsWire

Pipeline Insights for Seasonal Allergic Rhinitis, with Coverage of Allergy Therapeutics, Glenmark Pharmaceutical and VentiRx Pharmaceuticals

DUBLIN, April 29, 2020 /PRNewswire/ -- The "Seasonal Allergic Rhinitis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The Seasonal Allergic Rhinitis report provides a detailed picture of the pipeline landscape, together with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Products covered by Phase

    --  Phase III, Phase II, Phase I
    --  Pre-clinical & Discovery
    --  Inactive (Discontinued and Dormant)

Overview of pipeline development activities for Seasonal Allergic Rhinitis

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Seasonal Allergic Rhinitis

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Scope of the report

    --  Provides an overview of therapeutic pipeline activity for Seasonal
        Allergic Rhinitis across the complete product development cycle
        including all clinical and non-clinical stages
    --  It comprises of detailed profiles of Seasonal Allergic Rhinitis
        therapeutic products with key coverage of developmental activities
        including licensing & collaboration deals, patents issued, designations,
        technologies and chemical information
    --  Therapeutic assessment of the active pipeline products by stage, product
        type, molecule type, and route of administration
    --  Coverage of dormant and discontinued pipeline projects across Seasonal
        Allergic Rhinitis

Reasons to Buy

    --  Establish a comprehensive understanding of the current pipeline scenario
        across Seasonal Allergic Rhinitis to formulate effective R&D strategies
    --  Assess challenges and opportunities that influence Seasonal Allergic
        Rhinitis R&D
    --  Gather impartial perspective of strategies of the emerging competitors
        having potentially lucrative portfolio in this space and create
        effective counter strategies to gain competitive advantage
    --  Identify the relationship between the product and use it for target
        finding, drug repurposing, and precision medicine
    --  Devise in licensing and out licensing strategies by identifying
        prospective partners with progressing projects for Seasonal Allergic
        Rhinitis to enhance and expand business potential and scope
    --  The extensive domain knowledge on therapy areas support the client in
        decision-making process regarding their therapeutic portfolio by
        identifying the reason behind the inactive or discontinued drugs

Companies Mentioned 

    --  Allergy Therapeutics Plc
    --  Faes Farma
    --  Glenmark Pharmaceuticals Ltd.
    --  Hisamitsu Pharmaceutical Co.
    --  Merck & Co.
    --  Pfizer Inc.
    --  Shionogi & Co.
    --  VentiRx Pharmaceuticals

Key Topics Covered:

1. Report Introduction

2. Seasonal Allergic Rhinitis - Disease Overview

3. Pipeline Outlook

    --  An Overview of Pipeline Products for Seasonal Allergic Rhinitis

4. Comparative Analysis

5. Seasonal Allergic Rhinitis Therapeutic Products in Clinical Stage
5.1 Drug Name : Company Name

    --  Product Description
    --  Research and Development
    --  Product Development Activities

6. Seasonal Allergic Rhinitis Therapeutic Products in Non-clinical Stage
6.1 Drug Name : Company Name

    --  Product Description
    --  Research and Development
    --  Product Development Activities

7. Therapeutic Pipeline Analysis

    --  Pipeline Analysis by Route of Administration
    --  Pipeline Analysis by Stage and Route of Administration
    --  Pipeline Analysis by Molecule Type
    --  Pipeline Analysis by Stage and Molecule Type

8. Inactive Pipeline Products
8.1 Drug Description

    --  Research and Development Studies
    --  Product Development Activities
    --  Reason for dormancy/discontinuation

Appendix

Report Methodology


For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hhs46e

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/pipeline-insights-for-seasonal-allergic-rhinitis-with-coverage-of-allergy-therapeutics-glenmark-pharmaceutical-and-ventirx-pharmaceuticals-301049216.html

SOURCE Research and Markets